that has 47 million shares outstanding trading at 3 bucks for a vaue of $150 million
no revenue. no income. one name change (coronado biosciences to fortress, new name, new incarnation, there muste be a record for most name changes)and a cash burn bet on :
ortress Biotech, Inc., a biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. The company's principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201, a biologic comprising the microscopic eggs of the porcine whipworm for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis, or autism spectrum disorder; and CNDO-109, a biologic that activates the immune system's natural killer cells to seek and destroy cancer cells for the treatment of acute myeloid leukemia. It has strategic alliances and commercial agreements with Ovamed GmbHp; Dr. Falk Pharma GmbH; and Freie Universitt Berlin. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in Burlington, Massachusetts.
12 million shares short or a roughly $40 million bet against its survival
the play is purely in the trench. force the shorts to cover (buy back the shares sold short) through their pain threshold (stop loss)
absolutely nothing to do with the business
as an aside what could the challenge of been to have listed the elevated minds in produce ?
Comments